Fragile X Syndrome - Pipeline Review, H1 2017

Publisher Name :
Date: 11-Apr-2017
No. of pages: 108
Inquire Before Buying

Fragile X Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Fragile X Syndrome - Pipeline Review, H1 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fragile X Syndrome - Overview 6
Fragile X Syndrome - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Fragile X Syndrome - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Fragile X Syndrome - Companies Involved in Therapeutics Development 22
Aelis Farma SAS 22
AMO Pharma Ltd 22
Anavex Life Sciences Corp 23
Confluence Pharmaceuticals LLC 23
DRI Biosciences Corp 24
Eli Lilly and Company 24
Fulcrum Therapeutics Inc 25
GlaxoSmithKline Plc 25
GW Pharmaceuticals Plc 26
Marinus Pharmaceuticals Inc 26
Neuren Pharmaceuticals Ltd 27
Neuron Biopharma SA 27
Ovid Therapeutics Inc 28
Sage Therapeutics Inc 28
Zynerba Pharmaceuticals Inc 29
Fragile X Syndrome - Drug Profiles 30
acamprosate calcium - Drug Profile 30
ACT-01 - Drug Profile 31
AMO-01 - Drug Profile 32
ANAVEX-273 - Drug Profile 34
Bryostatin-1 - Drug Profile 44
cannabidiol - Drug Profile 49
cercosporamide - Drug Profile 54
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 56
flindokalner - Drug Profile 57
gaboxadol - Drug Profile 58
ganaxolone - Drug Profile 60
JRP-655 - Drug Profile 67
NNZ-2591 - Drug Profile 68
NST-0076 - Drug Profile 70
SAGE-217 - Drug Profile 71
SGE-872 - Drug Profile 74
Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile 75
Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile 76
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile 77
Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile 78
Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile 79
Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile 80
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 81
SRT-278 - Drug Profile 82
TC-2153 - Drug Profile 83
trofinetide - Drug Profile 84
Fragile X Syndrome - Dormant Projects 92
Fragile X Syndrome - Discontinued Products 94
Fragile X Syndrome - Product Development Milestones 95
Featured News & Press Releases 95
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List of Tables
Number of Products under Development for Fragile X Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fragile X Syndrome - Pipeline by Aelis Farma SAS, H1 2017
Fragile X Syndrome - Pipeline by AMO Pharma Ltd, H1 2017
Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2017
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H1 2017
Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H1 2017
Fragile X Syndrome - Pipeline by Eli Lilly and Company, H1 2017
Fragile X Syndrome - Pipeline by Fulcrum Therapeutics Inc, H1 2017
Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2017
Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H1 2017
Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc, H1 2017
Fragile X Syndrome - Pipeline by Sage Therapeutics Inc, H1 2017
Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Fragile X Syndrome - Dormant Projects, H1 2017
Fragile X Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017
Fragile X Syndrome - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Fragile X Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Substance Abuse Treatment Market Research Report 2017
    Published: 19-Oct-2017        Price: US 2900 Onwards        Pages: 101
    In this report, the global Substance Abuse Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Substance Abuse Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe ......
  • Global Varicose Vein Treatment Market Data Survey Report 2025
    Published: 19-Oct-2017        Price: US 1500 Onwards        Pages: 84
    Summary There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. The global Varicose Vein Treatment market will reach Volume Million USD in 2017 with CAGR xx% 2018-2025. The main contents of ......
  • United States Virus Like Particles Market Report 2017
    Published: 12-Oct-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Virus Like Particles market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • Global Virus Like Particles Sales Market Report 2017
    Published: 10-Oct-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Virus Like Particles market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Virus Like Particles for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Ja......
  • Heavy Metal Poisoning - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdomin......
  • Radiation Injury - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H2 2017, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure ca......
  • Low Back Pain - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 98
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2017, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in......
  • Binge Eating Disorder - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 62
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs ......
  • Global Microbiome Therapeutics Market Research Report 2017
    Published: 10-Oct-2017        Price: US 2900 Onwards        Pages: 127
    In this report, the global Microbiome Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Microbiome Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs